Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy
Related Experiment Video
Updated: Jul 17, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Thanyawee Puthanakit1, Linda Aurpibul, Peninnah Oberdorfer
1Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand 50202. tputhana@mail.med.cmu.ac.th
Insights
Highly active antiretroviral therapy (HAART) significantly reduced hospitalization and mortality in HIV-infected children. Most events occurred within the first 24 weeks of treatment, highlighting an early critical period for pediatric HIV care.
Area of Science:
- Pediatric Infectious Diseases
- Public Health in Resource-Limited Settings
- Antiretroviral Therapy Research
Background:
- Pediatric antiretroviral therapy (ART) programs are expanding in resource-limited settings.
- The impact of highly active antiretroviral therapy (HAART) on pediatric HIV cohorts in these areas requires further documentation.
- This study evaluated hospitalization and mortality rates in HIV-infected Thai children on HAART.
Purpose of the Study:
- To assess the rates and causes of hospitalization among HIV-infected Thai children receiving HAART.
- To determine the mortality rates in this pediatric cohort.
- To analyze the impact of HAART over time on clinical outcomes.
Main Methods:
- Prospective observation of antiretroviral-naive HIV-infected children (CD4% ≤15%) starting HAART between August 2002 and March 2005.
- Study included 192 children, with a minimum follow-up of 48 weeks.
- Data collected on age, CD4 cell percentage, plasma HIV RNA levels, hospitalizations, and mortality.
Main Results:
- Hospitalization rates decreased significantly from 30.7% in the first 24 weeks to 2.0% by weeks 120-144.
- Pneumonia and bacterial infections were the primary causes of hospitalization (61.7%), followed by immune reconstitution syndrome (23.4%).
- Mortality rates declined from 5.7% in the first 24 weeks to 0%-0.6% in subsequent periods.
Conclusions:
- HAART significantly reduced hospitalization and mortality in HIV-infected children.
- The initial 24 weeks of HAART represent a critical period for managing hospitalizations and mortality.
- Findings underscore the importance of close monitoring during early HAART initiation in pediatric HIV management.
Background:
Pediatric antiretroviral therapy programs have recently been implemented in resource-limited settings. Their impact in a prospective cohort is not well documented. The aim of this study was to evaluate the rates and causes of hospitalization and mortality among human immunodeficiency virus (HIV)-infected Thai children after receiving highly active antiretroviral therapy (HAART).
Methods:
Children who started receiving HAART from August 2002 to March 2005 were prospectively observed. The patients included in the study were antiretroviral-naive HIV-infected children who had CD4 cell percentages < or =15% before treatment. All patients were observed for at least 48 weeks.
Results:
One hundred ninety-two children were included. The mean age at HAART initiation was 7.6 years (range, 0.4-14.8 years). At baseline, the mean CD4 cell percentage (+/-SD) was 5.2%+/-4.9%, and the mean plasma HIV RNA level (+/-SD) was 5.4+/-0.5 log(10) copies/mL. Sixty-seven children (35%) were hospitalized a total of 108 times. The hospitalization rate decreased from 30.7% during the first 24-week period to 2.0% during weeks 120-144 after initiation of HAART. Fifty-nine hospital admissions (54.6%) occurred during the first 24 weeks of HAART. Causes of hospitalization were pneumonia and other bacterial infections (61.7%), immune reconstitution syndrome (23.4%), noninfectious illness (6.5%), opportunistic infection (5.6%), and drug-related events (2.8%). The mortality rate decreased from 5.7% in the first 24 weeks to 0%-0.6% in the subsequent 24-week intervals.
Conclusion:
Hospitalization and mortality rates significantly decreased among HIV-infected children receiving HAART. Most hospitalizations and deaths occurred during the first 24 weeks of HAART.
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Sexually Transmitted Infections
Cryptococcal Meningitis
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...

